A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

The initiative, Project Optimus, launched in 2021 just as Amgen was seeking to market sotorasib. At the time, the FDA’s leading cancer drug regulator, Richard Pazdur, co-wrote an editorial in ...

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting that combination therapy ...

Amgen points out that the study wasn't statistically ... likely serve as a confirmatory study for the approval of Lumakras (sotorasib) in this heavily pretreated patient population, which was ...

A new drug combination shows promise for colon cancer patients whose disease no longer responds to standard chemotherapy ...

The new study, conducted with support from Amgen Inc., builds on previous research by Dr. Fakih’s team that found sotorasib could be made more effective when combined with panitumumab.